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Strategies used in improving and  
assessing the level of reporting  
of implementation fidelity in  
randomised controlled trials of  
palliative care complex interventions:  
A systematic review
Kexin Ang1,2, Nilay Hepgul2, Wei Gao2 and Irene J Higginson2
Abstract
Background: Implementation fidelity is critical in evaluating effectiveness of interventions.
Aim: Identifying and summarising strategies to improve and assess the level of reporting of implementation fidelity in randomised 
controlled trials of palliative care complex interventions.
Design: Systematic review.
Data sources: Published and completed randomised controlled trials from 2000 to current evaluating effectiveness of specialised 
palliative care services on patient-centred outcomes in adult patients were examined. MEDLINE was searched from 2008 to 29 
September 2015 and supplemented by randomised controlled trials identified in a 2008 systematic review.
Results: Altogether, 20 randomised controlled trials involving 8426 patients were reviewed using 40 subcomponents of five elements 
of implementation fidelity (resulting in 20 × 40 = 800 items). Over 88 strategies were identified, classified under the following elements: 
‘treatment design’, ‘training providers’, ‘delivery of treatment’, ‘receipt of treatment’ and ‘enactment of treatment skills’. No single 
overarching strategy was discovered. Strategies under ‘treatment design’ aimed to ensure equivalent treatment dose between and 
within intervention and control groups, and delivery of necessary ingredients. Ongoing ‘training (of) providers’ included supervision 
and ensuring skill acquisition. Use of treatment manuals and implementation checklists aimed to aid ‘delivery of treatment’. Research 
teams aimed to improve ‘receipt of treatment’ by transmitting clear information and verifying understanding, while improving 
‘enactment of treatment skills’ by reviewing and reinforcing prior content. Only 26% of the items received sufficient reporting; 34% 
were either not used or reported on.
Conclusion: Implementation fidelity in palliative care is under-recognised. A table to collate these strategies to improve implementation 
fidelity in palliative care research and clinical practice is proposed.
Keywords
Health plan implementation, palliative care, palliative medicine
What is already known about the topic?
•• Palliative care is a complex intervention.
•• The effectiveness of an intervention can only be determined if there is implementation fidelity (meaning the extent an 
intervention is implemented as intended).
•• Current understanding of implementation fidelity and strategies to improve this have been largely derived from behav-
iour change interventions, but there has been no analysis of this for palliative care.
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Introduction
The two conditions for experimental interventions to be 
adopted as standard care are as follows: they are effective 
and were implemented with a minimum implementation 
fidelity standard. Implementation fidelity is important 
because without it, conclusive statements about the effec-
tiveness of an intervention cannot be made.1–8 However, 
implementation fidelity is challenging in palliative care. 
Current understanding of implementation fidelity is largely 
focused on interventions aimed at changing health behav-
iours,1,2,4,5,9 that is, behavioural change interventions, which 
often only makes up one component of palliative care. 
Therefore, behavioural change implementation fidelity 
strategies and findings may not be easily transferable to 
palliative care, a complex intervention. Palliative care, with 
a heterogeneous patient population both in terms of pri-
mary diagnosis and setting for service delivery,6 requires 
individualised care10 and becomes ineffective if any of its 
vital interacting components are left out.5,11 Therefore, 
understanding how to maintain and improve implementa-
tion fidelity in palliative care is especially important in 
order to avoid errors of poor implementation of complex 
interventions. In this systematic review, we aimed to iden-
tify and summarise strategies used in recently published 
randomised controlled trials (RCTs) of palliative care com-
plex interventions to improve implementation fidelity.
Methods
Theoretical framework and definitions of 
implementation fidelity
There is no consistent definition for implementation 
fidelity. For the purpose of this review, implementation 
fidelity is defined as ‘the extent an intervention is imple-
mented as intended’1,12 and interpreted to mean the same 
as ‘intervention fidelity’9 and ‘treatment fidelity’.2 In 
order to be inclusive, implementation ‘fidelity’ has also 
been interpreted to mean the same as ‘integrity’.2 Without 
a universally agreed definition for implementation fidel-
ity, some authors have taken an alternative approach to 
defining implementation fidelity by elucidating its essen-
tial elements. The current understanding of implementa-
tion fidelity by its elements is summarised, as in Figure 1, 
building on existing conceptual frameworks.2–4,9,12,13
As represented in Figure 1, implementation fidelity is 
thought to have six core elements (in dark blue) each with 
different components (in light blue). These are ‘context’, 
‘design’, ‘providers’, ‘delivery’, ‘receipt’ and ‘enactment’. 
Each corresponds to the various stages of an intervention 
and is examined sequentially below.
The first element is the ‘context’, or in other words, the 
‘surrounding social systems, such as structures and cul-
tures of organizations and groups, inter-organizational 
linkages, and historical as well as concurrent events’12 of 
the intervention. While relevant to recognise, ‘context’ is 
usually an uncontrollable variable so not many strategies 
are expected to result therefrom.
The second element is the ‘design’ which refers to the 
study’s ability to adequately test its hypotheses underlin-
ing its theory and clinical processes.2 As seen in Figure 1, 
‘design’ has five components.
The first component is the ‘theory’2 underlining the 
intervention. The second component is a comprehensive 
‘protocol’ or manual9 for implementation of the interven-
tion to ensure ease of replication and evaluation of the 
intervention, such as detailed guidelines, troubleshooting 
assistance and setting of standards. The third component is 
determination of the ‘dose’ and its ideal and minimally 
acceptable standards. ‘Dose’ refers to the frequency and 
duration of the intervention, and also the content of the 
What this paper adds?
•• Implementation fidelity in palliative care is under-recognised.
•• Strategies used to improve implementation fidelity in randomised controlled trials of palliative care can be categorised 
under the following elements: ‘treatment design’, ‘training providers’, ‘delivery of treatment’, ‘receipt of treatment’ and 
‘enactment of treatment skills’.
•• Over 88 strategies have been identified to improve implementation fidelity.
Implications for practice, theory or policy
•• A table, modified from the data extraction form used in this review, representing the elements of fidelity, their subcom-
ponents, and showcasing the strategies identified, has been produced.
•• The strategies identified could be used, not just in research but in clinical practice, to guide all phases of the development 
and evaluation of palliative care interventions.
•• Substantial administrative burden in the application of the identified strategies suggests that further investigation is 
required to identify which strategies are more effective in improving, as well as assessing, the level of reporting of imple-
mentation fidelity in palliative care interventions.
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Figure 1. Modified conceptual framework of implementation fidelity.
Adapted from existing conceptual frameworks by Bellg et al.,2 Carroll et al.,3 Hasson,12 Gearing et al.,9 Borrelli4 and Masterson-Algar et al.13
‘dose’ (inclusion of right active ingredients(s) necessary 
for desired outcomes to be achieved).3 To preserve flexi-
bility, guidance on adaptation can set parameters for dose 
variations.9 The fourth component is ‘staff’ (intervention 
providers) standards.9 The fifth and last component of 
‘design’ is ‘recruitment strategies’: procedures used to 
attract potential intervention participants,12 as this impacts 
the extent to which those eligible for the intervention par-
ticipate in it.3
The third element is the ‘providers’ who should be ade-
quately trained to deliver the intervention, and subjected to 
assessment and ongoing evaluation.2 This influences the 
quality of delivery, defined as the ‘extent to which the pro-
vider approaches a theoretical ideal’.3 This element con-
sists of six components: standardised ‘training’ and 
‘supervision’,3,9 measures to ensure ‘skill acquisition’ and 
‘maintenance’,3,4 and ‘participant responsiveness’ (the 
extent the providers are engaged in an intervention3), as 
well as countering ‘threats’ to fidelity.
The fourth element is ‘delivery’, which directly impacts 
quality of delivery.3 This entails monitoring that the inter-
vention is delivered as intended:2,3 following the ‘design’ 
(second element), delivering the intended ‘dose’, adher-
ence to ‘providers’ (third element) standards,2 ‘mainte-
nance’ of delivery standards over time and ‘feedback’ on 
collected fidelity data at each stage of the intervention 
resulting in corrective adjustments, to address further 
‘threats’.3,9 Finally, valid and reliable ‘measurement’ of 
exposures and outcomes9 are essential to maintaining 
delivery.
The fifth element is ‘receipt’ of the intervention. This 
assesses whether the participant receiving the intervention 
(assessed by quantity of ‘dose’ received in terms of 
frequency, duration and content), ‘comprehends’2,9 the 
intervention, and is able to demonstrate the knowledge or 
‘perform’ the intervention skills taught.2 ‘Participant 
responsiveness’, measuring participants’ engagement in 
the intervention, applies to this and to the next and final 
element – ‘enactment’.3
The sixth element ‘enactment’ refers to the intervention 
participant demonstrating knowledge or performing inter-
vention skills in relevant real-life settings.2
Design
We followed standard systematic review methods;14 the 
protocol was registered on PROSPERO and can be 
accessed at http://www.crd.york.ac.uk/PROSPERO/dis-
play_record.asp?ID=CRD42015027950.
Inclusion and exclusion criteria
Recently published (from 2000 to current) and completed 
RCTs which had evaluated the effectiveness of specialised 
palliative care (SPC) complex intervention services on 
patient-centred outcomes in adult palliative care patients 
were included. We took the view that these recently pub-
lished palliative care RCTs would be the most useful 
source of information on implementation fidelity and an 
efficient means for a systematic review, given the likeli-
hood that more comprehensive reporting will be found in 
RCTs which are high-quality evidence,15 and reporting of 
recent RCTs was seen to be of higher quality. Pilot and 
feasibility trials, and trials where only the protocol had 
been published, were excluded. Studies published in lan-
guages other than English were also excluded.
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We defined an SPC service as a professional service that 
provides or coordinates comprehensive care. This was also 
the definition used in Zimmermann et al.’s16 systematic 
review. Only multifaceted or multicomponent complex 
interventions were included. Drug or procedural trials, and 
trials evaluating singular variables, for example, communi-
cation, were excluded, in order to reflect the complexities of 
an SPC service. There were no exclusions based on the com-
parator interventions used as the aim of the review was to 
identify strategies for improving implementation fidelity, 
rather than assessing the effectiveness of interventions.
Trials were included if its participants were adult 
patients requiring palliative care. This meant adult patients 
with advanced, progressive, symptomatic and life-threat-
ening disease, for whom the focus of care is maximising 
their quality of life, through expert symptom management, 
psychological, social and spiritual support. Trials were 
excluded if the participants targeted were informal 
caregivers.
Trials were included if they reported on patient-centred 
outcomes (e.g. symptom control, quality of life, survival or 
satisfaction). Trials that only reported on one aspect of a 
patient-centred outcome (e.g. effectiveness of pain medi-
cation on pain) were excluded.
Search methods for identification of studies
The search was conducted using MEDLINE from 2008 to 
29 September 2015. This was supplemented by published 
RCTs from 2000 to January 2008 identified through 
Zimmermann et al.’s16 systematic review on the effective-
ness of SPC services. Key trials (Appendix 1) were identi-
fied by experts in the field of palliative care research (I.J.H. 
and W.G.). Keywords used in the final search were ‘pal-
liat$ or terminal$ or hospice$’, ‘quality of life or well 
being’ and ‘randomised controlled trial$ or randomized 
controlled trial$ or RCT or random allocation or randomi-
sation or randomization’. The detailed search strategy can 
be found in Appendix 2. Searching of other resources, such 
as grey literature, hand searching reference lists and cited 
reference searching was not done.
Data collection and analysis
Selection of studies. In considering inclusion/exclusion, a 
first decision was made by one researcher (K.A.) based on 
titles and abstracts available. A study was excluded if 
information clearly indicated that it did not meet the inclu-
sion criteria. When a decision could not be made with cer-
tainty, the full paper was inspected. Any doubt in the 
selection of studies was discussed with a second researcher 
(I.J.H.) and resolved through consensus. A record of 
excluded studies and the reasons for exclusion were kept.
Data extraction and management. Data extraction was car-
ried out on the included trials using the 40-item Treatment 
Fidelity Assessment and Implementation Plan checklist 
formulated by National Institutes of Health Behaviour 
Change Consortium (NIHBCC).4 This checklist was the 
most comprehensive and acceptable in pilot-test coding 
when compared against four other checklists5,9,17,18 from 
the literature review that informed the above-modified 
conceptual framework (Figure 1). Data extracted from 
each trial included the following: the author and year of 
publication, setting (country), number of patients in the 
trial, brief patient inclusion and exclusion criteria, brief 
description of the intervention and control intervention, 
brief research outcomes, the 40 items in the Treatment 
Fidelity Assessment and Implementation Plan checklist 
themselves4 and also whether or not other strategies out-
side of those coded in the checklist for use in behaviour 
change4 could be identified. The last item in the checklist4 
was amended from ‘a strategy would be used to assess per-
formance …’ (deemed a typo error) to ‘a strategy would be 
used to improve performance …’, as published in the origi-
nal Treatment Fidelity checklist.18
Where included trials referred readers to previously pub-
lished studies with likely additional information on imple-
mentation fidelity, these referenced studies were retrieved. 
This was to allow our review to be as inclusive and compre-
hensive as possible in gathering strategies for implementa-
tion fidelity. Strategies were coded on the same checklist 
such that only one checklist was generated for each trial. A 
record of the additionally retrieved studies was kept.
Each of the 40 items was rated with ‘A’ for ‘absent but 
should be present’ and ‘NA’ for ‘not applicable’.18 The ‘pre-
sent’ rating18 was differentiated9 into ‘++’ for ‘present suf-
ficiently’ (especially if there was detailed or extensive 
coverage/reporting) and ‘+’ for ‘present insufficiently’ 
(especially if only briefly mentioned, inferred or one was 
unsure if it fulfils criteria for ‘present sufficiently’). Empty 
space for free text was also provided such that even if insuf-
ficiently present, the strategy used for each of the items 
could be filled in. Strategies suggested in the ‘Discussion’ 
section of the included trials were also described in free text, 
even if the item was rated as ‘A’ for absent.
Standard rules for rating were set to maximise reliabil-
ity in coding, enable differentiation of ratings and optimise 
the checklist such that it would be applicable to palliative 
care. Examples provided by Borrelli4 were added to guide 
the coder on what to look out for. Two trials were also 
pilot-test coded independently by a second researcher 
(N.H.) and disagreement resolved with further refining of 
the standard rules. Where consensus was not achieved, the 
opinion of a third researcher (I.J.H.) was sought and the 
standard rules further refined to eliminate ambiguity.
Subcomponents of the modified conceptual framework 
(Figure 1) were also included, with ‘training’ for the pro-
viders interpreted to include supervision, and ‘participant 
responsiveness’ interpreted as a means to improve partici-
pant comprehension of the intervention. ‘Recruitment strat-
egies’ was not included as it was thought to be more relevant 
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to the fidelity of the trial, as opposed to the fidelity of the 
intervention which is the scope of this review.
K.A. is a physician, while NH holds a doctoral degree; 
both have a special interest in palliative care. I.J.H. is a 
consultant in specialist palliative care and also holds a doc-
toral degree. Inter-coder reliability was not calculated.
Data synthesis
Strategies identified through the data extraction form were 
coded on the 40-item checklist. Each item was rated ‘++’, 
‘+’, ‘A’ or ‘NA’ according to the level of reporting of the 
strategy and analysed in table form against the five core 
elements (the first element ‘context’ was not considered as 
it is usually an uncontrollable parameter):
•• ‘treatment design’, that is, whether the study is able 
to sufficiently test its hypotheses in relation to its 
underlying theory and clinical processes;2
•• ‘training providers’, that is, whether the providers 
are satisfactorily trained to deliver the intervention 
and are subjected to assessment and ongoing 
evaluation;2
•• ‘delivery of treatment’, that is, whether the inter-
vention is delivered as intended;2,3
•• ‘receipt of treatment’, that is, whether the interven-
tion participant has received and ‘comprehends’2,9 
the intervention, and is able to demonstrate the 
knowledge or ‘perform’ the intervention-related 
skills taught;2
•• ‘enactment of treatment skills’, that is, whether the 
intervention participant is able to demonstrate 
knowledge or perform intervention-related skills in 
relevant real-life settings.2
Results
A study flow diagram as recommended by the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement14 is illustrated in Figure 2.
Three papers were excluded upon full inspection. 
One of these was a quasi-experimental study19 and two 
were duplicate publications of results from the ENABLE 
II trial.20,21 The ENABLE II trial was excluded as the 
intervention was a nurse-led psychoeducation interven-
tion; however, the papers reporting the trial were 
included as they contain information relevant to imple-
mentation fidelity in ENABLE III.22 Another five pub-
lished RCTs from 2000 to January 2008 identified 
through Zimmermann et al.’s16 systematic review were 
excluded upon full inspection. Further details of the 
excluded studies can be found in Appendix 3.
Of the key trials used to ensure sensitivity of the search 
strategy, one could not be recovered in the final search 
strategy; it was included in the data analysis.23–26 Nine 
papers20,21,27–33 which had been referenced in the included 
trials were later added to the review as they were likely to 
contain additional information on strategies used for 
implementation fidelity.
Description of studies
A total of 46 papers reporting on 20 RCTs of SPC complex 
intervention services involving 8426 patients were 
included. In total, 10 trials were conducted exclusively with 
cancer patients,20–22,27,32–51 one exclusively on multiple 
sclerosis,23–26 one exclusively on chronic heart failure,52,53 
whereas the remaining eight trials were not confined to a 
single diagnostic group.28–31,54–65 All were carried out in 
developed countries with the majority being in the United 
States (nine of them)20–22,28,30,31,33,39–45,54–57,60–65 and in the 
United Kingdom (five).23–27,29,37,38,58,59
As the focus of this review was to extract implementa-
tion fidelity strategies rather than to evaluate the effective-
ness of the interventions used, only brief notes on the study 
participants, sample size, setting (country), intervention 
and outcome measured have been tabulated. This table of 
characteristics of included studies is in Appendix 4.
Strategies for improving implementation fidelity 
in RCTs of palliative care complex interventions
Under treatment design, an important subcomponent is to 
ensure the dose is equivalent between and within the inter-
vention and control groups, with similar access and atten-
tion to both groups38 and within each group. The latter 
could be via specifying the number of contacts29,58 with a 
proviso that this could be increased when necessary,38,46 or 
limiting the number of contacts (referring on if more is 
needed);23–26 specifying a range of minutes to be spent;48–50 
using a ‘structured-visit format’;55 or promoting protocol 
adherence, such as early site visits, review of medical 
records60 and conference calls.55,60 Other key strategies 
identified include (1) specification of provider credentials 
needed,47 (2) specification and incorporation of active 
ingredients, demonstrating treatment differentia-
tion,27,28,34–50,52–54,56,59 (3) use of expert/protocol review 
groups to determine implementation protocol fidelity to 
underlying theoretical model and (4) identification of 
potential confounders.
Under training providers, key strategies include provi-
sion of pre-implementation or ongoing training, such as 
observing experts, working with relevant clinicians, clarify-
ing of job scope,27,37 regular supervision sessions,20–22,27,33–37 
regular didactic sessions by experts,28,34–36,56 grand rounds, 
workshops and video presentations.30,31,61–65 Other strate-
gies include role-play practice sessions with feedback to 
assess provider skill acquisition,20–22,33 record and review of 
intervention sessions to assess provider skill mainte-
nance,20–22,33 assessment of providers’ suitability for particu-
lar interventions54 and appropriate training for trainees from 
different disciplines.30,31,61–65
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For treatment delivery, key strategies are the usage of a 
treatment manual,34–36 usage of an implementation check-
list,39–44 site visits/surveys to ensure adherence to interven-
tion plan,54,60 interviewing patients or caregivers on their 
experience,23–26,29,32,45,51–53,58 checking whether medications 
given were appropriate,32,51 limiting specific intervention 
to intervention group patients and preventing exposure 
by control group,59 and using a cluster randomised trial 
design,30–32,34–36,51,61–65 preferably with only one unit of ran-
domisation per cluster and restricting the intervention to 
trial sites.32,51
In relation to ‘delivery of treatment’, a summary table 
on the level of reporting of implementation fidelity is pre-
sented in Table 1, and the remaining summary tables for 
the remaining core elements (excluding ‘context’) are pre-
sented in Appendix 5. As can be seen from Table 1, only 
Figure 2. PRISMA flowchart.
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about one-third (62 items) of the strategies were suffi-
ciently reported (rated ‘++’), while another third (60 
items) were either not used or reported (rated ‘A’); none of 
the trials mentioned having set a standard for implementa-
tion fidelity that the trial would have to meet.
For receipt of treatment, key strategies are having a 
health literacy component,55 having patients recall interven-
tion suggestions, considering ‘participant responsiveness’ 
and recruitment of willing patients,34–36 assisting with 
understanding of medical terminology,55 providing access to 
information adjusted for health literacy,28,55,56 answering 
questions,28,38,56 verifying understanding,28,39–44,56 summa-
rising information29,58,60 and providing an information 
pack.29,58 Rehearsal of emergency situations and practising 
self-monitoring and reporting of patients’ results28,56 would 
aid in assessment of patients’ receipt. Consideration of 
cross-cultural communication in the educational compo-
nent,30,31,61–65 amending feedback method for outcome data 
by removing ranking numbers, de-identifying comments, 
emphasising positive findings and positively presenting low 
score as opportunities for improvement30,31,61–65 were used 
to improve receipt.
Finally, key strategies for assessment of enactment include 
checking self-monitoring diaries, the status of earlier referrals 
and compliance with medical regime,28,29,56,58 while reinforc-
ing prior content20–22,28,29,33,56,58 improves enactment.
These strategies are summarised in Table 2 (in black 
text). No other strategies for improving implementation 
fidelity outside of the elements used in behaviour change 
and coded outside the checklist4 were identified. We also 
did not find examples of strategies that tried to alter the 
context of the implementation environment to facilitate 
implementation of the intervention.
Out of the 800 items rated (40 items for each of the 20 
trials), 270 items were rated ‘A’ (34%), 159 ‘+’ (20%), 
209 ‘++’ (26%) and 162 ‘NA’ (20%). When the individ-
ual trial was considered, less than 50% of the 40 items 
were rated ‘++’. The detailed extracted data are available 
from the corresponding author. Appendix 6, sorted into the 
five core elements (excluding ‘context’), presents a sum-
mary of strategies used and suggested, including the strate-
gies which were insufficiently described, for improving 
implementation fidelity.
Discussion
This is the first systematic review of strategies used to 
improve implementation fidelity in RCTs of palliative care 
complex interventions. By reviewing and rating 20 recently 
published SPC service RCTs involving 8426 patients, we 
have shown that implementation fidelity in palliative care 
is under-recognised, with up to a third of assessed items 
rated ‘absent’ and another 20% insufficiently reported on. 
Moreover, it does not seem that the studies had intention-
ally reported on implementation fidelity. Nevertheless, 
over 88 strategies have been identified, sub-classified 
under the following elements: ‘treatment design’, ‘training 
providers’, ‘delivery of treatment’, ‘receipt of treatment’ 
and ‘enactment of treatment skills’. The list of strategies 
for each item should be viewed as a whole rather than indi-
vidually as certain items rated absent may still have been 
accomplished partially in other items. Strategies were not 
mutually exclusive and can support several goals. The use 
of these strategies, albeit mostly in cancer patients in 
developed countries, suggests that the strategies are appli-
cable to other palliative care RCTs.
Strategies in palliative care covered all subcomponents 
except for two: (1) having a plan to ensure that the meas-
ures reflect the hypothesised theoretical constructs/mecha-
nisms of action and (2) an a priori specification of treatment 
fidelity. Although a potential source of administrative bur-
den, theoretical underpinnings have been recognised as 
crucial for the success in complex interventions.66 
Similarly, high fidelity requires at least 80% adherence, 
with 50% considered low.4 Although palliative care is a 
complex intervention, of which behaviour change may 
only constitute one component, no additional strategies 
outside of those coded in the checklist for use in behaviour 
change4 could be identified. This suggests that strategies 
used in behaviour change and other fields, not yet identi-
fied as used in palliative care RCTs, may be used to 
improve implementation fidelity in palliative care RCTs 
and palliative care interventions in general, and that pallia-
tive care researchers could work more closely with behav-
iour change researchers.
As such, Table 2, modified from the data extraction 
form used in this review, incorporates examples of strate-
gies used in behaviour change interventions4 in green text. 
The strategies identified in this review have also been 
added on to the data extraction form in black text, as exam-
ples of strategies used in palliative care trials, for use in 
assessing the level of reporting of implementation fidelity. 
These examples provided would assist future coders on 
what to look for. The standard rules used in data extraction 
are in red text.
The strategies identified in this review could be used, 
not just in research but in clinical practice, to guide all 
phases of the development and evaluation of palliative 
care interventions,66 to ensure that they are implemented 
more efficiently and produce more trustworthy results. 
However, there is also substantial administrative burden in 
the practical application of these strategies. Administrative 
burden is brought on by evaluating the ‘delivery of treat-
ment’ and also in ‘training providers’ by having to assess 
skill acquisition in intervention providers trained to deliver 
the intervention, and to continually evaluate that they have 
maintained their skills.
An additional column for strategies identified from 
papers other than the main paper dealing with the trial has 
also been added to the data extraction form used in this 
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Table 2. Recommended data extraction form along with the standard rules and examples of strategies used.
Trial identifier by author and year of publication of results Use this column to 
code information that 
was not found in the 
original article
Setting (country)
Number of patients
Brief patient inclusion and exclusion criteria
Brief description of intervention vs control
Brief research outcomes
Treatment design
1. Provide information about treatment dose planned for in the intervention condition  
  (a) Length of contact (minutes) (no need to elaborate) (NA if the dose is on an as-needed basis)  
  (b) Number of contacts (no need to elaborate) (NA if the dose is on an as-needed basis)  
  (c) Content of treatment (no need to elaborate)  
  (d) Duration of contact over time (no need to elaborate)  
 2. Provide information about treatment dose planned for in the comparison condition  
  (a) Length of contact (minutes) (no need to elaborate) (NA if the dose is on an as-needed basis)  
  (b) Number of contacts (no need to elaborate) (NA if the dose is on an as-needed basis)  
  (c)  Content of treatment (no need to elaborate) (+ if only mentions ‘usual care’/absence of the 
intervention implying usual care, without further elaboration of what usual care constitutes)
 
  (d) Duration of contact over time (no need to elaborate) (NA if the dose is on an as-needed basis)  
  (e)  Method to ensure that dose is equivalent between conditions (NA if the dose is on an as-needed 
basis)
E.g. Provide similar access and attention to both groups (withholding only the intervention)
 
  (f)  Method to ensure that dose is equivalent for participants within conditions (NA if the dose is on an 
as-needed basis; ++ if adequately describes the dose and can, where applicable, be equivalent for 
each subject)
E.g. Specify the number of contacts; and add a proviso that this could be increased when necessary; 
limit the number of contacts (refer on if more is needed); specify a range of minutes to be spent; use a 
‘structured-visit format’; promote protocol adherence, such as early site visits, review of medical records 
and conference calls
 
 3.  Specification of provider credentials that are needed (+ if only the professional discipline is known; ++ 
If level of experience is known)
E.g. Specify professional discipline and level of experience, e.g., specialist nurse with more than 10 years of 
experience in oncology nursing care
 
 4. Theoretical model upon which the intervention is based is clearly articulated  
  (a)  The active ingredients are specified and incorporated into the intervention (+ if elaborates on what 
the essential components of the intervention might be; ++ if explains factors distinguishing it from 
the comparison condition, i.e., differentiation)
E.g. Specify and incorporate essential components of the intervention, and how the intervention differs 
from the control group
 
  (b)  Use of experts or protocol review group to determine whether the intervention protocol reflects 
the underlying theoretical model or clinical guidelines (+ if self-derives protocol from reviews 
or known theoretical models; ++ if uses a panel of experts, protocol review group or advisory 
committee)
E.g. Provide reasons for selecting the intervention evaluated, e.g., reviews or theoretical models, and 
use experts or protocol review group. Examples used were: cooperative study group, project advisory 
committee, project advisory group and trial study group
 
  (c)  Plan to ensure that the measures reflect the hypothesised theoretical constructs/mechanisms 
of action (++ if the outcome measures selected and used by the study adequately assesses the 
hypothesised theory behind the intervention)
 
 (Continued)
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 5.  Potential confounders that limit the ability to make conclusions at the end of the trial are identified 
(A if confounders identified was that there was no method to ensure the dose equivalence within 
or between treatment groups; + if baseline demographics measured, or baseline outcome measures 
measured; ++ if other confounders identified, or if strategies to get around confounders used)
E.g. Measure baseline demographics and baseline outcome measures, where applicable
Additional confounders identified were as follows: evaluating a recently started existing service such that 
the providers involved have not had sufficient experience with the intervention routines; relying on existing 
community services which may be limited in palliative care competence and resources; the extra attention 
the intervention group would get; the complexity of the intervention and heterogeneity of the patient 
group; having a relative who was an intervention provider or working with one; the exclusion of a patient 
group that was most likely to benefit
Sources of contamination were as follows: a focus on palliative care by providers for the control group 
regardless of whether it was brought on by publicity on palliative care, education of control group 
providers as part of the intervention or provider participation in both arms; access by the control group to 
palliative and supportive interventions
Strategies: recruit patients early in their disease trajectories, yet frequently symptomatic, with a higher 
likelihood of participating and benefiting from the intervention; obtain administrative and clinical backing; 
address common obstacles in palliative care, such as inability or unwillingness to engage in decision-making, 
early in the intervention
 
 6.  Plan to address possible setbacks in implementation (i.e. backup systems or providers) (++ even if only 
mentioned having sufficient manpower)
E.g. Have adequate manpower (but this was not foolproof as large numbers increase unreliability, which 
warrant minimising with training); a backup system, e.g., repeated video-screening giving all targeted 
participants an opportunity to view the video
 
 7.  If more than one intervention is described, all described equally well (NA if two-armed RCT)  
Training providers
 1.  Description of how providers will be trained (manual of training procedures) (interpreted to include 
supervision and maintenance protocols) (NA if all the providers designed intervention/uses existing 
service; + if only mentioned that there was training provided, ++ if details on training methods for 
either pre-implementation or ongoing training of providers are available)
E.g. Pre-implementation training: observing experts; working with relevant clinicians; clarifying of job scope; 
making links with providers of similar services; independent reading; role-playing with feedback
Methods used for ongoing training: regular telephone calls or meetings to discuss implementation issues; 
regular supervision sessions; regular advice; joint visits if necessary; regular didactic sessions by experts, 
grand rounds, workshops, or video presentations; system supports such as palliative care order forms 
that facilitate learning through personal experience; spontaneous teaching moments and discussions of 
clinical cases; bedside training; coaching, telephone and direct guidance; identification and training of local 
champions; feedback of quality data; clinical audits for difficult cases; reviewing implementation to develop 
more appropriate training strategies; using suitable tools for consolidation of the changes
 
 2.  Standardisation of provider training (especially if multiple waves of training are needed for multiple 
groups of providers) (NA if only one trainee/if all the providers designed intervention/used existing 
service; + if inferred ‘standardisation’ or only standardised a component of the intervention)
E.g. Use the same trainers over time, use certified trainers, train all providers together, use standardised 
training materials, use video or audio tapes of expert delivery, develop a manual of training procedures and 
videotape trainings in case of provider attrition and need for future trainings
 
 3.  Assessment of provider skill acquisition (interpreted to be pre-implementation of intervention; + if 
‘assessment’ inferred, ++ if details provided on how the assessment was done)
E.g. Use role-plays with standardised patients followed by feedback to provider, score provider adherence 
to both intervention content and process using validated performance criteria, have a written exam pre and 
post training, develop criteria for initial certification
E.g. Practice sessions in the form of role-playing with feedback
 
Table 2. (Continued)
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 4.  Assessment and monitoring of provider skill maintenance over time (+ if ‘supervision/feedback’ is 
inferred; ++ if details provided on assessing or monitoring)
E.g. Booster sessions, patient exit interviews, periodic re- certification, audio or video record all encounters 
and code for treatment adherence, provide timely feedback, monitor patient drop-out rates of each 
provider
E.g. Review intervention patients’ medical records; review audio-recorded intervention sessions; assess 
inter-rater reliability of assessments by providers against that by research associates; collection and 
feedback of outcome data and meetings to discuss barriers to achieving the outcome
 
 5.  Characteristics being sought in a treatment provider are articulated a priori. Characteristics that should 
be avoided in a treatment provider are articulated a priori (A if only provider credentials mentioned; NA 
if all the providers designed intervention/used existing service; + if inferred that providers were chosen)
E.g. Choose providers of appropriate disciplines with appropriate skills; or who have ‘institutional identity 
and credibility’ being familiar with institutional policies and having ongoing relationships with clinicians 
whom they would need to work together with in the intervention
 
 6.  At the hiring stage, assessment of whether or not there is a good fit between the provider and the 
intervention (e.g. ensure that providers find the intervention acceptable, credible, and potentially 
efficacious) (NA if all the providers designed intervention/used existing service; + if inferred that the 
providers found the intervention potentially efficacious prior to the start of the trial)
E.g. Hire providers with similar credentials and experience. Ensure ‘buy in’ to treatment, theory and 
randomisation. Consider matching providers to key characteristics of the population
E.g. Enhance buy-in from providers: Foster provider self-efficacy and perception of organisational support. 
Explain the study design and rationale, the principles of research and why it is important to prevent 
contamination and omission or addition of components not specified by the intervention
E.g. Conduct intervention at centres which already have a similar service and which the provider is 
interested in evaluating its new yet similar service
 
 7.  There is a training plan that takes into account trainees’ different education and experience and learning 
styles (NA if all the providers designed intervention/used existing service)
E.g. Design training for diverse learning styles, train providers to deal with different types of participants, 
consider more intensive training and follow-up for less experienced providers
E.g. Train different disciplines differently; evaluate its implementation mid-way to develop an appropriate 
strategy for the subsequent implementation stages
 
Delivery of treatment  
 1.  Method to ensure that the dose of the intervention is delivered as specified (interpreted ‘as specified’ as 
‘adequate levels’; dose here excludes content) (+ if used a treatment protocol, or if details of treatment 
are available; ++ if there is both assessment and feedback of dosage, or if provider records number of 
contact minutes or uses a checklist)
E.g. Use an implementation checklist; use a template (according to protocol guidance) in the electronic 
medical record to document the care provided
 
 2.  Method to ensure that the content of the intervention is delivered as specified (interpreted ‘as specified’ 
as ‘adequate levels’) (+ if used a treatment protocol, or if details of treatment are available; ++ if 
there is both assessment and feedback of dosage, or if provider records care given on a standardised 
questionnaire, has to report protocol deviations, or uses a checklist)
E.g. Use an implementation checklist; use a template (according to protocol guidance) in the electronic 
medical record to document how much of the visit was spent on each element of the intervention
 
 3.  Mechanism to assess if the provider actually adhered to the intervention plan or in the case of 
computer delivered interventions, method to assess participants’ contact with the information (+ if 
mentioned; ++ if details provided)
E.g. Site visits or surveys; regular telephone conferences; regular meetings; interview patients or their formal 
caregivers; participant observation by research staff at site meetings; monitoring administrative databases; 
examine treatment implementation checklists for a randomly selected subset of patients; review audio-
recorded intervention sessions for adherence; take attendance at intervention sessions; keep patient records
 
 (Continued)
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 4.  Assessment of non-specific treatment effects (e.g. empathy, communication style) (+ if inferred assessment; 
++ if purpose of interview was focussed on assessing non-specific treatment effects, or experience)
E.g. Assess non-specific effects through multiple methods and on an ongoing basis (patient exit interview, 
audiotape and code sessions, monitor participant complaints, provide feedback to provider)
E.g. Ask patients and/or carers about their experiences of the intervention
 
 5.  Use of treatment manual (++ if details were provided, or if the word ‘manual’ or its synonyms, e.g., 
protocol were used)
E.g. Use scripted curriculum or treatment manual
 
 6.  There is a plan for the assessment of whether or not the active ingredients were delivered (+ if 
inferred that there is a plan; ++ if data was collected for such purpose and details on how it was 
collected is available)
E.g. Apart from reporting on mechanisms available for assessment of provider adherence, trials were required 
to report that data were collected for such purpose and provide details on how the data were collected
This included the following: site visits or surveys; regular telephone conferences; regular meetings; 
interviewing patients; participant observation by research staff at site meetings; monitor administrative 
databases; examine treatment implementation checklists for a randomly selected subset of patients; review 
audio-recorded intervention sessions for adherence; take attendance at intervention sessions; review 
patient records
 
 7.  There is a plan for the assessment of whether or not proscribed components were delivered (e.g. 
components that are unnecessary or unhelpful) (+ if inferred that there is a plan or enquired about 
experiences; ++ if purpose of interview was focussed on assessing negative non-specific treatment 
effects or experiences)
E.g. Judged if medications given had been inappropriate
 
 8.  There is a plan for how will contamination between conditions be prevented
E.g. Limit access to the specific intervention evaluated to intervention group patients; limit control 
group exposure by using a limited form of the intervention and discouraging crossover unless absolutely 
necessary; use a cluster randomised trial design preferably with only one unit of randomisation per cluster 
and restricting the intervention to trial sites; being the only provider for specialist palliative care; keeping 
control patients’ details from the provider to avoid inadvertent contact; disqualifying patients who may have 
relatives working as or with intervention providers
Similarly, a strategy for preventing contamination in the intervention group included limiting their access to 
control group interventions, e.g., by making the intervention providers responsible for the entire care of 
the patients
 
 9.  There is an a priori specification of treatment fidelity (e.g. providers adhere to delivering >80% of 
components)
E.g. Establish minimum competency levels, below which providers are given remedial training (e.g. 
adherence to ⩽80% of the components)
 
Receipt of treatment
 1.  There is an assessment of the degree to which participants understood the intervention (+if inferred 
assessment or training)
E.g. Have a health literacy component; have patients recall intervention suggestions, such as who to contact 
after hours, resources available, and self-management of illness; assess patients’ illness and prognostic 
understanding; assess patients’ understanding of explanations given
 
 2.  There are specification of strategies that will be used to improve participant comprehension of 
the intervention (interpreted engaging patient (participant responsiveness) as a means to improve 
comprehension of the intervention; A if only mentioned ‘training’; + if strategy inferred; ++ even if 
one component of the intervention, as long as it was explicitly to improve comprehension)
E.g. Consider ‘participant responsiveness’ and recruit only willing patients; assist understanding of 
medical terminology; provide access to information adjusted for health literacy; answer questions; verify 
understanding; summarise information; provide an information pack; use lectures, video and pamphlets; 
reinforce prior content; provide access to personally relevant resources
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 3.  The participants’ ability to perform the intervention skills will be assessed during the intervention 
period (interpreted the intervention period as while the palliative care direct contact is taking place. 
In interventions without educational components, this would be, e.g., filling up the diary in front of 
the provider vs enactment, e.g., filling up the diary in between contact with the provider. Facilitating 
discussions or goal setting is thought of as an intervention rather than a performance of skills during the 
intervention period)) (+ if inferred assessment/training)
E.g. ‘Rehearse’ emergency situations and ‘practice’ self-monitoring and reporting of results with patients
 
 4.  A strategy will be used to improve subject performance of intervention skills during the intervention 
period (interpreted the intervention period as while the palliative care direct contact is taking place) (A 
if only mentioned ‘training’; + if strategy inferred)
E.g. Rehearse emergency situations; practicing self-monitoring and reporting of results
 
 5.  Multicultural factors considered in the development and delivery of the intervention (e.g. provided in 
native language; protocol is consistent with the values of the target group) (A if native language is the 
language of the majority)
E.g. Encourage local adaptation of order forms and pamphlets; amend feedback method for outcome 
data by removing ranking numbers, de-identifying comments, emphasising positive findings and positively 
presenting low score as opportunities for improvement
 
Enactment of treatment skills
 1.  Participant performance of the intervention skills will be assessed in settings in which the intervention 
might be applied (e.g. filling up the diary in between contact with the provider or self-management in 
times of crises. Facilitating discussions, decisions or goal-setting is thought of as an intervention rather 
than a performance of skills) (+ if inferred assessment)
E.g. Check self-monitoring diaries; check status of earlier referrals; check compliance with medication 
regime; check use of interventions, e.g., hand held fan for breathlessness
 
 2.  A strategy will be used to improve performance of the intervention skills in settings in which the 
intervention might be applied (A if only mentioned ‘training’; + if inferred; ++ even if one component 
of the intervention, as long as it was explicitly to improve enactment)
E.g. Reinforce prior content; have written instructions of the intervention written and laminated (in a poem 
or in a chart)
 
Strategies that are not included in any of these boxes  
Coding scheme: ‘A’ for ‘absent but should be present’; ‘NA’ for ‘not applicable’; ‘++’ for ‘present sufficiently’ especially if there was detailed or 
extensive coverage; ‘+’ for ‘present insufficiently’ especially if it was briefly mentioned, inferred, or one was unsure if it fulfils criteria for ‘present 
sufficiently’.
Each grey area is one component.
Colour code: quotes from the National Institutes of Health Behaviour Change Consortium (NIHBCC)4 are in blue, standard rules inserted by the 
author in red, examples provided by Borrelli4 in green and examples (strategies rated ‘++’) from the current review provided in black.
Table 2. (Continued)
review (see Table 2). The proportion of trials in which a 
strategy had been sufficiently present, or the mean propor-
tion of adherence to strategies for each trial, could then be 
calculated.18
With the use of the TIDieR checklist and guide,67 which 
aims to improve the completeness of reporting of interven-
tions by supplementing the CONSORT68 and SPIRIT69 
statements, and which has 2 out of its 12 items dedicated to 
fidelity, the level of reporting of interventions is likely to 
improve. The TIDieR checklist and guide67 suggest that 
both the planning and actual delivery of an intervention in 
terms of fidelity should be described, and that the descrip-
tion should include how intervention fidelity was ‘assessed 
and by whom, the strategies that were used to maintain or 
improve fidelity’, and the extent to which the intervention 
was delivered as planned (which also pertains to ‘delivery 
of treatment’). The use of Table 2 could also improve levels 
of reporting and reduce the proportion of items rated ‘A’. 
Table 2 could be updated if additional strategies are identi-
fied. The proportion of ‘A’ and ‘+’ ratings could also be 
used to track if the reporting of implementation fidelity has 
improved over time and provide an estimate of the accepta-
bility and interpretability of the table when reporting and 
awareness of implementation fidelity are optimised.
Aside from Table 2, to optimise face and content valid-
ity, it would be best to consult an international implemen-
tation fidelity workgroup in palliative care to ensure that 
the modified checklist captures the views of all these 
stakeholders. Consensus on what would constitute a suffi-
cient level of reporting, especially in the differentiation 
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between ‘+ and ‘++, and ‘A’ and ‘NA’, and if each strat-
egy identified ought to be scored individually, and whether 
certain aspects of implementation fidelity should be more 
heavily weighted than others, could be sought. The ques-
tion of how much information on implementation fidelity 
is needed for an informed decision as to whether or not the 
intervention was implemented with a minimum implemen-
tation fidelity standard, and therefore adequately evaluated 
the intervention tested, can then be answered.
Limitations
This review is subjected to biases. There was bias in sample 
selection from searching only MEDLINE for completed 
RCTs on adult patients that were published in English, 
although experts in palliative care research were consulted 
to identify key trials (Appendix 1) to ensure that the final 
sample of trials retrieved would be as representative as pos-
sible. We also did not search trial registers for other papers 
reporting our included trials, for example, process evalua-
tions. This could be a limitation of the study if papers 
detailing implementation fidelity were published at a later 
date. Measurement bias likely prejudices the level of imple-
mentation fidelity found in each trial, given the wide varia-
tion in level of reporting and limited word count in single 
publications, although data from multiple reports of the 
same trials were extracted onto a single checklist. To 
improve reporting in single publications, authors could be 
encouraged to publish fidelity information in an online 
resource and in their appended study protocol.
Conclusion
Implementation fidelity in palliative care is under-recog-
nised. Nevertheless, over 88 strategies have been identi-
fied in palliative care RCTs. The use of these strategies and 
those identified in behavioural change interventions, along 
with greater awareness on the subcomponents of the ele-
ments of implementation fidelity (see Table 2), will be 
valuable in improving, as well as evaluating, implementa-
tion fidelity. Needless to say, more funds are needed in pal-
liative care for education to maintain the minimum fidelity 
standard, facilitate the implementation of essential compo-
nents of a complex intervention and to support the devel-
opment and evaluation of research and clinical services.70
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